Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Dodecyl Maltoside
2. Dodecyl(-beta-d-)maltoside
3. Lauryl Maltoside
4. N-dodecyl-beta-d-maltoside
1. 69227-93-6
2. N-dodecyl-beta-d-maltoside
3. Lauryl Maltoside
4. Dodecyl Maltoside
5. N-dodecyl B-d-maltoside
6. N-dodecyl Beta-d-maltoside
7. N-dodecyl-
8. A-d-maltoside
9. Dodecyl Beta-maltoside
10. Dodecyl Beta-d-maltoside
11. Chebi:43769
12. Dodecyl B-d-maltopyranoside
13. Di107e57b4
14. Mfcd00043012
15. (2r,3r,4s,5s,6r)-2-(((2r,3s,4r,5r,6r)-6-(dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
16. Dodecyl 4-o-alpha-d-glucopyranosyl-beta-d-glucopyranoside
17. N-dodecyl-b-d-maltoside
18. Unii-di107e57b4
19. Lauryl Beta-maltoside
20. Dodecyl -d-maltoside
21. Lauryl Beta-d-maltoside
22. N-dodecyl-i(2)-d-maltoside
23. Schembl411624
24. Chembl1234047
25. Dtxsid30988948
26. Lauryl-.beta.-d-maltoside
27. Zinc16051829
28. N-dodecyl .beta.-d-maltoside
29. Akos016011222
30. Dodecyl 4-o-hexopyranosylhexopyranoside
31. Ds-6568
32. (2r,3r,4s,5s,6r)-2-((2r,3s,4r,5r,6r)-6-(dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2h-pyran-3-yloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
33. (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
34. Hy-128974
35. N-dodecyl Beta-d-maltoside, >=98% (gc)
36. Cs-0102968
37. 1-o-n-dodecyl-.beta.-dmaltopyranoside
38. F14800
39. 227d936
40. A866883
41. N-dodecyl Beta-d-maltoside, Bioxtra, >=98% (gc)
42. B-d-glucopyranoside, Dodecyl 4-o-a-d-glucopyranosyl-
43. Q27120527
44. Beta-d-glucopyranoside, Dodecyl 4-o-alpha-d-glucopyranosyl-
45. Dodecyl Alpha-d-glucopyranosyl-9(1->4)-beta-d-glucopyranoside
46. Wurcs=2.0/2,2,1/[a2122h-1b_1-5_1*occcccccccccc][a2122h-1a_1-5]/1-2/a4-b1
Molecular Weight | 510.6 g/mol |
---|---|
Molecular Formula | C24H46O11 |
XLogP3 | 1.4 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 16 |
Exact Mass | 510.30401228 g/mol |
Monoisotopic Mass | 510.30401228 g/mol |
Topological Polar Surface Area | 179 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 554 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 10 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Detergents
Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40294
Submission : 2024-10-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40558
Submission : 2024-10-17
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35918
Submission : 2021-05-25
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9248
Submission : 1991-07-03
Status : Inactive
Type : II
Details:
Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Microorganism
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2024
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 05, 2024
Details:
Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Microorganism
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 01, 2023
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
November 01, 2023
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG).
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Microorganism
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 01, 2023
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 01, 2023
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Microorganism
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2023
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pemb...
Details : CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
April 10, 2023
Details:
CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Microorganism
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2022
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab)...
Details : CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
October 24, 2022
Details:
The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Microorganism
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2022
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 04, 2022
Details:
Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Lead Product(s): Cretostimogene Grenadenorepvec,Dodecyl Maltoside
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Microorganism
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 30, 2020
Lead Product(s) : Cretostimogene Grenadenorepvec,Dodecyl Maltoside
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cretostimogene Grenadenorepvec is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 30, 2020
Details:
CG0070 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Microorganism
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2020
Lead Product(s) : CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CG0070 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 13, 2020
Market Place
Reply
22 Apr 2025
Reply
27 May 2023
Reply
05 Nov 2020
ABOUT THIS PAGE
44
PharmaCompass offers a list of Dodecyl Maltoside API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dodecyl Maltoside manufacturer or Dodecyl Maltoside supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dodecyl Maltoside manufacturer or Dodecyl Maltoside supplier.
PharmaCompass also assists you with knowing the Dodecyl Maltoside API Price utilized in the formulation of products. Dodecyl Maltoside API Price is not always fixed or binding as the Dodecyl Maltoside Price is obtained through a variety of data sources. The Dodecyl Maltoside Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dodecyl Maltoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dodecyl Maltoside, including repackagers and relabelers. The FDA regulates Dodecyl Maltoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dodecyl Maltoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dodecyl Maltoside supplier is an individual or a company that provides Dodecyl Maltoside active pharmaceutical ingredient (API) or Dodecyl Maltoside finished formulations upon request. The Dodecyl Maltoside suppliers may include Dodecyl Maltoside API manufacturers, exporters, distributors and traders.
click here to find a list of Dodecyl Maltoside suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dodecyl Maltoside DMF (Drug Master File) is a document detailing the whole manufacturing process of Dodecyl Maltoside active pharmaceutical ingredient (API) in detail. Different forms of Dodecyl Maltoside DMFs exist exist since differing nations have different regulations, such as Dodecyl Maltoside USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dodecyl Maltoside DMF submitted to regulatory agencies in the US is known as a USDMF. Dodecyl Maltoside USDMF includes data on Dodecyl Maltoside's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dodecyl Maltoside USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dodecyl Maltoside suppliers with USDMF on PharmaCompass.
Dodecyl Maltoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dodecyl Maltoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dodecyl Maltoside GMP manufacturer or Dodecyl Maltoside GMP API supplier for your needs.
A Dodecyl Maltoside CoA (Certificate of Analysis) is a formal document that attests to Dodecyl Maltoside's compliance with Dodecyl Maltoside specifications and serves as a tool for batch-level quality control.
Dodecyl Maltoside CoA mostly includes findings from lab analyses of a specific batch. For each Dodecyl Maltoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dodecyl Maltoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Dodecyl Maltoside EP), Dodecyl Maltoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dodecyl Maltoside USP).